http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Savara Announces New Leadership Appointments
-
Savara Announces New Employment Inducement Grant
-
Savara Announces New Employment Inducement Grant
-
Savara Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Savara to Participate in Three Upcoming Investor Conferences
-
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022
-
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Savara (SVRA) Announces Chief Medical Officer Resignation
-
Savara Announces Resignation of Chief Medical Officer
-
Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022
-
Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic
-
Savara to Present at Jefferies Healthcare Conference
-
Savara to Present at H.C. Wainwright Global Investment Conference
-
Savara Reports First Quarter 2022 Financial Results and Provides Business Update
-
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank
-
Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update
-
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference
-
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
-
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Savara to Participate in Two Upcoming Investor Healthcare Conferences
-
Savara Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Savara to Present at the Jefferies London Healthcare Conference
-
Savara to Present at the Inaugural Piper Sandler Lung Day
-
Savara to Participate in Two Upcoming Investor Healthcare Conferences
-
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Savara Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
-
Savara to Present at the Jefferies Virtual Healthcare Conference
-
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
-
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Savara Reports First Quarter 2021 Financial Results and Provides Business Update
-
Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option
-
Savara (SVRA) Prices Public Offering of Common Stock, Warrants
-
Savara Announces Pricing of Public Offering of Common Stock
-
Savara (SVRA) Announces Proposed Public Offering of Common Stock
-
Savara Announces Proposed Public Offering of Common Stock
-
Savara (SVRA) Provides Pipeline and Business Update
-
Savara Provides Pipeline and Business Update
-
Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences
-
Savara to Present at the Jefferies Virtual London Healthcare Conference
-
Savara Reports Third Quarter 2020 Financial Results and Provides Business Update
-
Savara Announces Senior Management Changes
-
Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually
-
Savara (SVRA) Announces NEJM Publication of IMPALA Study Results

